Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative join forces to combat vision loss from diabetes 12-11-2024, 17:10

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

Synchronoss Technologies Announces Fourth Quarter and Full Year 2024 Earnings Call Date 26-02-2025, 04:05